Curis (CRIS) AI Stock Analysis

• Market Cap: $10.40M
• Dividend Yield: N/A
• Average Volume (3M): 68.01K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.64
• Revenue Growth: 13.56%
• EPS Growth: 52.92%
• Country: US
• Employees: 34
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 1.23
• Shares Outstanding: 13,734,939
• 10 Day Avg. Volume: 74,344
• 30 Day Avg. Volume: 68,010
• PEG Ratio: 0.02
• Price to Book (P/B): -3.22
• Price to Sales (P/S): 1.77
• P/FCF Ratio: -0.49
• Enterprise Value/Market Cap: 0.51
• Enterprise Value/Revenue: 0.46
• Enterprise Value/Gross Profit: 0.46
• Enterprise Value/Ebitda: -0.16
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -1.73
• Revenue Forecast (FY): $12.52M

• Rating: 45 Neutral
• Price Target: $0.89 ▼(-12.18% Downside)
• Action: Reiterated Date: 01/09/26
• Date: Action: Reiterated 01/09/26

The score is held down primarily by weak financial durability (negative equity, higher debt, and continued cash burn) and bearish technicals (below key moving averages with negative MACD). Offsetting factors include constructive clinical/program updates and financing actions that may extend runway, but execution and funding/dilution risks remain central.

Positive Factors

High-margin revenue growth

Strong trailing-twelve-month revenue growth combined with near-100% gross margins indicates the company’s core products/rights have very favorable unit economics. This supports long-term scalability and attractive incremental margins once operating losses moderate or fixed costs are absorbed.

Advancing emavusertib clinical programs

Progress toward accelerated submissions for PCNSL and active initiation of CLL proof-of-concept represent structural clinical milestones. Successful regulatory filings or positive pivotal data would transform the company’s risk profile, enable partnerships/licensing, and materially improve long-term commercialization prospects.

PIPE financing extends runway

The structured PIPE provides substantial committed capital that extends runway into 2027 and supports planned clinical pivots. This reduces immediate solvency pressure, funds execution of key development milestones, and increases the odds of reaching value-inflection events before cash depletion.

Negative Factors

Negative shareholders' equity and rising debt

A shift to negative equity and a large increase in debt materially weaken financial resilience. This structural balance-sheet deterioration raises refinancing, covenant and solvency risks, constrains strategic choices, and increases likelihood of dilutive financings or unfavorable credit terms over the medium term.

Persistent negative free cash flow

Consistent negative operating and free cash flow shows the company cannot self-fund growth and must rely on external financing. That structural cash-generation gap limits strategic flexibility, raises dilution risk, and makes long-term investment plans contingent on capital markets or partner deals.

Limited cash reserves and near-term funding need

A low cash balance (~$9.1M) creates an immediate funding imperative that can force near-term equity raises or partnership deals. Such urgency risks dilutive financings, compressed negotiating leverage, and potential delays to clinical programs if capital is not secured on acceptable terms.

Curis Business Overview & Revenue Model

Company Description

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

How the Company Makes Money

Curis generates revenue through a combination of product sales, licensing agreements, and collaborations. The primary revenue stream comes from the development and commercialization of its drug candidates, which may include upfront payments, milestone payments, and royalties from partnered products. The company also engages in strategic partnerships with larger pharmaceutical companies, which provide funding for research and development in exchange for rights to market or co-develop certain products. Additionally, Curis may receive government grants or funding for specific research initiatives, further contributing to its earnings.

Curis Financial Statement Overview

Summary

Strong TTM revenue growth and near-100% gross margin are positives, but the financial profile is dominated by very large losses and persistent negative free cash flow. The shift to negative equity and the sharp rise in debt materially increase solvency and dilution/refinancing risk.

Income Statement

TTM (Trailing-Twelve-Months) revenue is growing strongly versus the prior annual period (growth rate ~215%), and gross margin remains near 100%, consistent with high-margin biotech revenue streams. However, profitability is deeply negative: TTM net margin is about -314% with substantial operating losses (EBIT and EBITDA also significantly negative), indicating the business is still far from break-even and reliant on external funding or partnerships to cover operating costs.

Balance Sheet

The balance sheet weakened materially: stockholders’ equity moved from positive in 2023 to negative in 2024 and remains negative in TTM (Trailing-Twelve-Months), which is a major credit and financing risk signal. Debt increased sharply in TTM to ~$30.6M from ~$3.0M in 2024, and the debt-to-equity measure is distorted by negative equity but still highlights elevated leverage risk. Total assets also declined significantly from 2023 to TTM, reducing balance-sheet flexibility.

Cash Flow

Cash generation remains a key concern: operating cash flow and free cash flow are negative across all periods, including TTM (Trailing-Twelve-Months) free cash flow of about -$30.1M. There is improvement versus 2024 (cash burn reduced from roughly -$39.6M), but the TTM free cash flow decline rate is unfavorable and the company continues to fund losses with financing rather than internally generated cash.

Breakdown	TTM	Mar 2025	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	11.65M	10.91M	10.02M	10.16M	10.65M	10.84M
Gross Profit	11.59M	10.81M	9.81M	9.90M	10.12M	10.30M
EBITDA	-33.20M	-42.57M	-45.14M	-51.67M	-40.81M	-24.67M
Net Income	-36.56M	-43.39M	-47.41M	-56.67M	-45.44M	-29.91M
Balance Sheet
Total Assets	27.64M	41.27M	77.28M	108.85M	162.30M	204.36M
Cash, Cash Equivalents and Short-Term Investments	9.05M	20.00M	56.33M	85.62M	115.88M	168.49M
Total Debt	30.60M	2.95M	2.79M	3.94M	5.04M	7.66M
Total Liabilities	42.33M	47.26M	57.61M	62.30M	71.59M	73.69M
Stockholders Equity	-14.69M	-6.00M	19.67M	46.55M	90.71M	130.67M
Cash Flow
Free Cash Flow	-30.09M	-39.56M	-38.43M	-54.75M	-37.62M	-26.42M
Operating Cash Flow	-30.09M	-39.56M	-38.43M	-54.34M	-37.62M	-25.74M
Investing Cash Flow	-428.00K	29.44M	37.79M	33.02M	-47.90M	-49.05M
Financing Cash Flow	18.71M	3.44M	7.58M	867.00K	-4.17M	188.81M

Curis Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRIS, the sentiment is Negative. The current price of 1.01 is below the 20-day moving average (MA) of 1.02, above the 50-day MA of 0.98, and below the 200-day MA of 1.48, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 33.44 is Neutral, neither overbought nor oversold. The STOCH value of 7.60 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRIS.

Curis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RLYB	67 Neutral	$48.08M	-3.44	-21.17%	―	12.71%	79.93%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BGMS	47 Neutral	$4.51M	-0.94	-226.28%	10.27%	9.46%	96.85%
CRIS	45 Neutral	$10.40M	-17.14	354.21%	―	13.56%	52.92%
MBRX	45 Neutral	$10.99M	-1.17	―	―	―	79.31%
PULM	43 Neutral	$7.85M	-1.58	-79.47%	―	-99.97%	35.59%

Curis Corporate Events

Curis Announces PIPE Financing and Strategic Capital Strengthening

On January 7, 2026, Curis entered into a private placement securities purchase agreement with healthcare-focused institutional investors and company insiders for a PIPE financing structured around 20,195 shares of Series B convertible non-redeemable preferred stock bundled with three tranches of warrants, priced at $1,000 per unit and exercisable at $0.75 per share, which together could yield up to approximately $80.8 million in gross proceeds if all warrants are exercised, including about $20.2 million expected at closing on or about January 8, 2026. The complex preferred and warrant package is designed to convert into common stock following shareholder approval and is accompanied by registration rights for resale, while Curis plans to use the initial proceeds, alongside existing cash, to fund research and development and general corporate purposes, extend its cash runway into 2027, support its strategic pivot toward emavusertib combination trials in chronic lymphocytic leukemia and primary CNS lymphoma, and bolster stockholders’ equity as it seeks to maintain compliance with Nasdaq Capital Market listing standards after prior delisting warnings tied to market value and equity thresholds.

The most recent analyst rating on (CRIS) stock is a Hold with a $0.82 price target. To see the full list of analyst forecasts on Curis stock, see the CRIS Stock Forecast page.

Curis Completes Sale of Erivedge Business

On November 6, 2025, Curis completed the sale of its Erivedge Business to TPC Investments Royalty LLC, managed by Oberland, for $2.5 million and a release of liability related to future royalties. This transaction will result in a gain for Curis in the fourth quarter of 2025 and extinguish its royalty-related liabilities, although it will no longer receive revenues under the License Agreement. Additionally, Curis is actively pursuing compliance with Nasdaq listing requirements after receiving an exception period until November 14, 2025, to meet the market value listing standard. The company is also advancing its clinical studies in PCNSL, CLL, and AML, with significant progress in enrolling patients and presenting data at upcoming conferences, which could potentially enhance its market positioning and stakeholder confidence.

The most recent analyst rating on (CRIS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Curis stock, see the CRIS Stock Forecast page.